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Immunotherapy, harnessing the immune system to combat cancers, has yielded promising results in patient care. Monoclonal antibodies that block the "immune checkpoint" through PD-1, PD-L1, or CTLA-4 have demonstrated impressive clinical activities against a variety of tumors ([@bib1]). However, durable benefit is only observed in a small fraction of patients. Identifying patients that will likely respond and extending the therapies to a larger population both require a better understanding of PD-1 and CTLA-4 function at the cell biological level. Here, the current knowledge of the cell biological mechanisms of PD-1, PD-L1, and CTLA-4 and their blocking antibodies is summarized.

The ability of conventional T (Tcon) cells to target tumor cells depends on two types of signals. The first is an antigen-specific signal through the T cell receptor (TCR). TCR recognizes a peptide antigen presented by major histocompatibility complex (MHC) molecules on tumor cells or tumor-infiltrating antigen-presenting cells (APCs), and converts the extracellular binding event to highly coordinated intracellular signaling cascades that lead to T cell proliferation, cytokine production, and cytolytic activities. Initially, TCR-associated CD3 subunits become phosphorylated and recruit and activate the kinase ZAP70. ZAP70 phosphorylates the membrane adaptor LAT, leading to multivalent interactions between LAT, adaptors, and enzymes to form a signaling hub at the membrane. The LAT "signalosome" triggers Ca^2+^ signaling, cytoskeleton remodeling, and MAPK signaling to activate the T cell transcriptional program ([@bib2]). The second type of signal is antigen-unspecific, mediated by cosignaling receptors---costimulatory, increasing the T cell response, or coinhibitory, attenuating T cell activity ([@bib3])---triggered by ligands on tumor cells or tumor-infiltrating APCs. CD28 is a prominent costimulatory receptor, whereas PD-1 and CTLA-4 are coinhibitory receptors. Upon binding to its ligand B7-1 or B7-2, displayed by APCs but not tumor cells, CD28 is phosphorylated and recruits kinases PKCθ, ITK, and PI3K to facilitate TCR signaling.

PD-1 on T cells is activated by its ligand PD-L1, expressed by diverse cell types, and present on exosomes. PD-L1/PD-1 binding triggers PD-1 phosphorylation and recruitment of the SHP2 phosphatase. PD-1--associated SHP2 dephosphorylates CD28 and TCR signaling components to inhibit the T cell response. Mechanisms other than SHP2 may exist, as suggested by a SHP2 knockout study ([@bib4]). While operating as a brake to restrict over-reactive T cells and autoimmunity, PD-1 can be hijacked by tumors to evade immune surveillance. Normally, PD-1 expression on T cells is induced by TCR signaling and decreases to basal levels upon antigen clearance. Persistent antigen stimulation in the tumor microenvironment can lead to constitutively high PD-1 expression. Moreover, a variety of mechanisms can up-regulate PD-L1 in tumor tissues. Besides operating as the PD-1 ligand, PD-L1 was recently shown to inhibit interferon/STAT3-mediated apoptosis of tumor cells ([@bib5]). The FDA has approved several PD-L1/PD-1 blocking antibodies for cancer immunotherapy, including anti-PD-1 (Pembrolizumab, Nivolumab, and Cemiplimab) and anti-PD-L1 (Atezolizumab, Avelumab, and Durvalumab).

CTLA-4 shares ligands with CD28: B7-1 and B7-2. Due to its higher affinity to B7 molecules, CTLA-4 can outcompete CD28 for these ligands. In Tcon cells, CTLA-4 is largely localized to intracellular vesicles and delivered to the cell surface upon TCR stimulation ([@bib6]). CTLA-4 surface levels critically determine the response to self-antigens or immunotherapy. Importantly, mounting evidence establishes a pivotal role of CTLA-4 on regulatory T (Treg) cells---T cells with suppressive activity. Treg-intrinsic CTLA-4 is able to deplete B7 molecules from APCs via trans-endocytosis ([@bib7]), which occurs in a PKCη-promoted manner ([@bib8]). Many believe that CTLA-4 blockade antibodies (e.g., Ipilimumab) work primarily by blocking or depleting Tregs. Interestingly, Tregs in the tumor microenvironment express higher surface levels of CTLA-4 than Tregs at other sites ([@bib9]). To what extent blocking Tcon-intrinsic CTLA-4 contributes to the therapeutic response is unknown.

Cosignaling receptors other than CTLA-4 are less well understood in Tregs. CD28 appears to support Treg function. Treg-intrinsic CD28 induces Ezh2 ([@bib10]), a chromatin-modifying enzyme that up-regulates the Treg-maintaining transcription factor Foxp3. The function of PD-1 in Tregs is controversial and how PD-1/PD-L1 blockade affects Tregs needs further investigation.

Lastly, while tumor immunity is mostly studied in the context of T cells, more work is needed to understand the contributions of other immune cells, such as macrophages, dendritic cells, neutrophils, and natural killer cells ([@bib11]). The quickly developing field of immune checkpoint blockade fuels renewed interest in the fundamental cell biological mechanisms of T cell function and regulation in the tumor microenvironment.
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